Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$7.00
-1.9%
$6.23
$3.93
$7.54
$358.70M1.551.03 million shs697,397 shs
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
$5.49
+1.8%
$4.41
$1.14
$7.20
$329.13M0.761.20 million shs530,258 shs
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1.72
+0.9%
$1.71
$0.63
$2.75
$91.68M0.521.74 million shs735,962 shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$5.65
+2.5%
$4.64
$2.86
$13.93
$388.10M1.92881,104 shs237,186 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.00%+13.90%+8.19%+14.45%+42.60%
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
0.00%+2.47%0.00%+122.73%+6.31%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
0.00%+13.33%+7.59%+31.78%+26.87%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
0.00%+18.75%+24.94%+14.79%-54.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
4.5665 of 5 stars
3.52.00.04.53.82.51.3
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
2.0457 of 5 stars
3.31.00.00.02.51.70.6
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
1.4435 of 5 stars
3.21.00.00.01.12.50.0
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
2.1336 of 5 stars
3.30.00.00.03.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
3.00
Buy$19.50178.77% Upside
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
2.67
Moderate Buy$9.5073.20% Upside
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
2.40
Hold$7.00308.16% Upside
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
2.67
Moderate Buy$24.00325.16% Upside

Current Analyst Ratings Breakdown

Latest MIST, ABEO, OLMA, and ALDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
8/15/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$19.00 ➝ $20.00
8/14/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$28.00 ➝ $29.00
8/12/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $21.00
8/11/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell
8/8/2025
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
7/14/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/5/2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$5.00
6/2/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$19.00
5/19/2025
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$3.50M102.49N/AN/A$1.01 per share6.93
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/A$1.19 per shareN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
$1M91.68N/AN/A$0.25 per share6.86
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/A$7.14 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$63.73M$0.709.99N/AN/AN/A150.05%59.86%N/A
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-$55.85M-$0.85N/AN/AN/AN/A-73.63%-50.61%11/6/2025 (Estimated)
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$41.52M-$0.84N/AN/AN/AN/A-1,672.29%-83.09%N/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%N/A

Latest MIST, ABEO, OLMA, and ALDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$0.39$1.71+$2.10$1.71$21.71 million$0.40 million
8/12/2025Q2 2025
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
-$0.18-$0.20-$0.02-$0.20N/AN/A
8/11/2025Q2 2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$0.43-$0.51-$0.08-$0.51N/AN/A
8/7/2025Q2 2025
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-$0.21-$0.16+$0.05-$0.16$1.08 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/AN/AN/AN/AN/A
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/AN/A
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
N/AN/AN/AN/AN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.27
4.90
4.90
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
N/A
2.86
2.86
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
4.06
4.97
4.97
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
0.01
11.09
11.09

Institutional Ownership

CompanyInstitutional Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
80.56%
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
59.71%
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
86.18%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
91.78%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
9051.28 million48.51 millionOptionable
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
1059.90 million54.81 millionOptionable
Milestone Pharmaceuticals Inc. stock logo
MIST
Milestone Pharmaceuticals
3053.46 million43.04 millionOptionable
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
7068.63 million57.41 millionOptionable

Recent News About These Companies

Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $21.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abeona Therapeutics stock logo

Abeona Therapeutics NASDAQ:ABEO

$7.00 -0.14 (-1.89%)
As of 02:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Aldeyra Therapeutics stock logo

Aldeyra Therapeutics NASDAQ:ALDX

$5.48 +0.10 (+1.76%)
As of 02:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Milestone Pharmaceuticals stock logo

Milestone Pharmaceuticals NASDAQ:MIST

$1.72 +0.02 (+0.88%)
As of 02:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Olema Pharmaceuticals stock logo

Olema Pharmaceuticals NASDAQ:OLMA

$5.64 +0.14 (+2.45%)
As of 02:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.